View in EDS PDF Full Text

Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.

Saved in:
Bibliographic Details
Title: Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.
Authors: Jung SH; Department of Biochemistry, IRCGP, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea., Lee CK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Sondang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Kwon WS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Yun S; Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea., Jung M; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Sondang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Sondang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Chung HC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Sondang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Chung YJ; Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea.; Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea. yejun@catholic.ac.kr., Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Sondang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac.
Source: Yonsei medical journal [Yonsei Med J] 2023 Sep; Vol. 64 (9), pp. 531-540.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
Journal Info: Publisher: Yonsei University Country of Publication: Korea (South) NLM ID: 0414003 Publication Model: Print Cited Medium: Internet ISSN: 1976-2437 (Electronic) Linking ISSN: 05135796 NLM ISO Abbreviation: Yonsei Med J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1976-2437
DOI:10.3349/ymj.2023.0096